[Current therapeutic methods in onco-hematology].
These next years, many anticancer drugs will be available with new mechanism of action. The taxoïd compounds: Taxol and Taxotere have been judged efficous in the treatment of advanced ovary and breast cancers. Also, DNA-Topoisomerase I inhibitors, a new enzyme molecular target, will expand solid tumors therapeutic strategies. The adenosine analogs represent the xnewest advances in hematology: fludarabine becomes the second line treatment for chronic lymphoïd leukemia, cladribine the reference treatment for hairy cell leukemia. At least, all-trans retinoïc acid has changed acute promyelocytic leukemia pronostic by differentiating tumor cells, and open a very new way of cancer treatment. All these agents are the first compounds available, others are still in development. They, all, are benefit of a productive research.
Madelaine-Chambrin
I
I
Service Pharmacie, Hôpital Saint-Louis, Paris.
Piquet-Sevrin
V
V
Faure
P
P
D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D014212:Tretinoin / Q000627:therapeutic use; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D007641:Keratolytic Agents; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D000077143:Docetaxel; D017338:Cladribine; D014212:Tretinoin; D014740:Vidarabine; C024352:fludarabine; D017239:Paclitaxel
Actualités thérapeutiques en onco-hématologie.